Importantly, B7 had a distinct anti‐GBM mechanism of action that targeted CD155 via interaction at five key binding interfaces within the B7‐CD155 complex, while simultaneously modulating the TIME through the CD155/TIGIT/CD226 axis. The gene discussed is CD226; the disease is glioblastoma.